Po Hien Ear, PhD
@pohienear.bsky.social
Assistant Professor, U Iowa Surgery Department, Neuroendocrine Tumors, Rare cancers, #nanets2024 Symposium Chair, sharing my own thoughts
It was such a great honor to be at #ENETS2025
I saw so many NET super stars 🤩🤩🤩 but I was too shy to go talk to them.
I finally summed up my courage to ask 2 of them (Profs de Herder & Hofland) for a selfie.
More next time…
I saw so many NET super stars 🤩🤩🤩 but I was too shy to go talk to them.
I finally summed up my courage to ask 2 of them (Profs de Herder & Hofland) for a selfie.
More next time…
March 10, 2025 at 1:33 AM
It was such a great honor to be at #ENETS2025
I saw so many NET super stars 🤩🤩🤩 but I was too shy to go talk to them.
I finally summed up my courage to ask 2 of them (Profs de Herder & Hofland) for a selfie.
More next time…
I saw so many NET super stars 🤩🤩🤩 but I was too shy to go talk to them.
I finally summed up my courage to ask 2 of them (Profs de Herder & Hofland) for a selfie.
More next time…
@endocrineoncology.bsky.social is in great hands with outstanding expertises from profs Castano & Glasberg!
Endocrine Oncology is run by a highly prestigious Editorial Board led by Editor-in-Chief, Professor @justocastano.bsky.social and Deputy Editor, Professor @simonaglasberg.bsky.social
Explore our international Editorial Board 👉 buff.ly/4icYTIK
Explore our international Editorial Board 👉 buff.ly/4icYTIK
March 10, 2025 at 1:23 AM
@endocrineoncology.bsky.social is in great hands with outstanding expertises from profs Castano & Glasberg!
Reposted by Po Hien Ear, PhD
Preparing for the ENETS annual conference next month. Here is a simplified vision of what might be the future in the world of radioligand therapy for NETs (RLT which I now prefer over PRRT as a term...).
Need better predictors of efficacy and tox
I have never been good at predicting...
Need better predictors of efficacy and tox
I have never been good at predicting...
February 23, 2025 at 6:06 PM
Preparing for the ENETS annual conference next month. Here is a simplified vision of what might be the future in the world of radioligand therapy for NETs (RLT which I now prefer over PRRT as a term...).
Need better predictors of efficacy and tox
I have never been good at predicting...
Need better predictors of efficacy and tox
I have never been good at predicting...
Reposted by Po Hien Ear, PhD
Congratulations to our founding member & former ENETS Chair, Philippe Ruszniewski, on receiving the ENETS Life Achievement Award 2025 from ENETS Chair Rocio Garcia-Carbonero. A well-deserved honour for his dedication and lifelong contributions to ENETS & NET science.
Thank you, Philippe!
#ENETS2025
Thank you, Philippe!
#ENETS2025
March 6, 2025 at 3:33 PM
Congratulations to our founding member & former ENETS Chair, Philippe Ruszniewski, on receiving the ENETS Life Achievement Award 2025 from ENETS Chair Rocio Garcia-Carbonero. A well-deserved honour for his dedication and lifelong contributions to ENETS & NET science.
Thank you, Philippe!
#ENETS2025
Thank you, Philippe!
#ENETS2025
Reposted by Po Hien Ear, PhD
🔥 from #ENETS25 - 🇨🇦 science on a big stage!💪🏻
@iacovosmichael.bsky.social using NETs organoids (my NET babies!) to test new Rx mechanisms
▪️apoptosis machinery active in G1/2 NETs
▪️BH3-mimetics + lutathera work in lab
👉🏻 New therapy to trial?
#NETsky #oncSky @nanets.bsky.social
@iacovosmichael.bsky.social using NETs organoids (my NET babies!) to test new Rx mechanisms
▪️apoptosis machinery active in G1/2 NETs
▪️BH3-mimetics + lutathera work in lab
👉🏻 New therapy to trial?
#NETsky #oncSky @nanets.bsky.social
March 6, 2025 at 2:28 PM
🔥 from #ENETS25 - 🇨🇦 science on a big stage!💪🏻
@iacovosmichael.bsky.social using NETs organoids (my NET babies!) to test new Rx mechanisms
▪️apoptosis machinery active in G1/2 NETs
▪️BH3-mimetics + lutathera work in lab
👉🏻 New therapy to trial?
#NETsky #oncSky @nanets.bsky.social
@iacovosmichael.bsky.social using NETs organoids (my NET babies!) to test new Rx mechanisms
▪️apoptosis machinery active in G1/2 NETs
▪️BH3-mimetics + lutathera work in lab
👉🏻 New therapy to trial?
#NETsky #oncSky @nanets.bsky.social
Reposted by Po Hien Ear, PhD
Get to know the new CUTNETs group!
Clinical care, research & training to be combined to ⬆️ surgical care of NETs 🇨🇦🇮🇹🇺🇸🇲🇽🇬🇧🇳🇴🇸🇪🇦🇹🇩🇪🇳🇱
Stay tuned for our research agenda and first collaborative studies 🦓🤝
in @bjsurgery.bsky.social 🔗 tinyurl.com/5n6e8w84
#NETSky #SurgSky #OncSky @nanets.bsky.social
Clinical care, research & training to be combined to ⬆️ surgical care of NETs 🇨🇦🇮🇹🇺🇸🇲🇽🇬🇧🇳🇴🇸🇪🇦🇹🇩🇪🇳🇱
Stay tuned for our research agenda and first collaborative studies 🦓🤝
in @bjsurgery.bsky.social 🔗 tinyurl.com/5n6e8w84
#NETSky #SurgSky #OncSky @nanets.bsky.social
Care of neuroendocrine tumours: the Collaborative of sUrgical Teams for NeuroEndocrine Tumors (CUTNETs)
Neuroendocrine tumours (NETs) are a diverse group of malignancies with rising incidence and complex behaviours1,2. Although surgical management is a critic
tinyurl.com
February 6, 2025 at 3:04 PM
Get to know the new CUTNETs group!
Clinical care, research & training to be combined to ⬆️ surgical care of NETs 🇨🇦🇮🇹🇺🇸🇲🇽🇬🇧🇳🇴🇸🇪🇦🇹🇩🇪🇳🇱
Stay tuned for our research agenda and first collaborative studies 🦓🤝
in @bjsurgery.bsky.social 🔗 tinyurl.com/5n6e8w84
#NETSky #SurgSky #OncSky @nanets.bsky.social
Clinical care, research & training to be combined to ⬆️ surgical care of NETs 🇨🇦🇮🇹🇺🇸🇲🇽🇬🇧🇳🇴🇸🇪🇦🇹🇩🇪🇳🇱
Stay tuned for our research agenda and first collaborative studies 🦓🤝
in @bjsurgery.bsky.social 🔗 tinyurl.com/5n6e8w84
#NETSky #SurgSky #OncSky @nanets.bsky.social
Reposted by Po Hien Ear, PhD
Because you can resect does not mean you should
Not all NETs are the same
Stefano Partelli introducing biological unresectability for PNETs at #ENETS25 👉🏻 identifying futile surgery & when preop therapy will help
We have 💊options - let’s figure out how to combine with surgery!
#NETsky #Medsky
Not all NETs are the same
Stefano Partelli introducing biological unresectability for PNETs at #ENETS25 👉🏻 identifying futile surgery & when preop therapy will help
We have 💊options - let’s figure out how to combine with surgery!
#NETsky #Medsky
March 6, 2025 at 4:46 PM
Reposted by Po Hien Ear, PhD
We're here at #ENETS2025 with Editor-in-Chief @justocastano.bsky.social , publisher Katherine and publishing assistant Brittany, representing the journal in beautiful Kraków!
If you're attending the conference come tell us about your next publication 🤝
If you're attending the conference come tell us about your next publication 🤝
March 6, 2025 at 8:30 AM
We're here at #ENETS2025 with Editor-in-Chief @justocastano.bsky.social , publisher Katherine and publishing assistant Brittany, representing the journal in beautiful Kraków!
If you're attending the conference come tell us about your next publication 🤝
If you're attending the conference come tell us about your next publication 🤝
Reposted by Po Hien Ear, PhD
Not many posts yet for #AACR25 in the #OncSky network, but there is bound to be in the run-up to the @theaacr.bsky.social Annual Meeting taking place in 7 weeks in #Chicago.
With increased scientific discourse on #Bluesky in recent weeks/months, looking forward to updates here throughout the meeting
With increased scientific discourse on #Bluesky in recent weeks/months, looking forward to updates here throughout the meeting
The AACR/American Association for Cancer Research is on #Bluesky: @theaacr.bsky.social - Enriching #OncSky engagement as a great build-up to #AACR25 taking place April 25-30, 2025 in Chicago, which will also mark the 27th year of the AACR Scientist↔Survivor Program®
www.aacr.org/patients-car...
www.aacr.org/patients-car...
March 6, 2025 at 9:10 PM
Not many posts yet for #AACR25 in the #OncSky network, but there is bound to be in the run-up to the @theaacr.bsky.social Annual Meeting taking place in 7 weeks in #Chicago.
With increased scientific discourse on #Bluesky in recent weeks/months, looking forward to updates here throughout the meeting
With increased scientific discourse on #Bluesky in recent weeks/months, looking forward to updates here throughout the meeting
Reposted by Po Hien Ear, PhD
More info on the this upcoming @moltherapy.bsky.social @cellpress.bsky.social Webinar taking place March 18, and the link for free registration:
www.workcast.com/register?cpa...
The content is a good preview for #AACR25 !
www.workcast.com/register?cpa...
The content is a good preview for #AACR25 !
March 7, 2025 at 7:20 PM
More info on the this upcoming @moltherapy.bsky.social @cellpress.bsky.social Webinar taking place March 18, and the link for free registration:
www.workcast.com/register?cpa...
The content is a good preview for #AACR25 !
www.workcast.com/register?cpa...
The content is a good preview for #AACR25 !
Reposted by Po Hien Ear, PhD
📸 Endocrine Oncology publishing team and our Deputy Editor Simona Glasberg ( @simonaglasberg.bsky.social ) at #ENETS2025 in Kraków!
@enets.bsky.social
@enets.bsky.social
March 7, 2025 at 10:49 AM
📸 Endocrine Oncology publishing team and our Deputy Editor Simona Glasberg ( @simonaglasberg.bsky.social ) at #ENETS2025 in Kraków!
@enets.bsky.social
@enets.bsky.social
Reposted by Po Hien Ear, PhD
Day 3 at #ENETS2025! Pictured is Editor-in-Chief Justo Castaño ( @justocastano.bsky.social ) finishing up his talk on best basic science NET publications of the year! ✨ if you’d like to find out more information on Endocrine Oncology visit eo.bioscientifica.com
March 7, 2025 at 12:00 PM
Day 3 at #ENETS2025! Pictured is Editor-in-Chief Justo Castaño ( @justocastano.bsky.social ) finishing up his talk on best basic science NET publications of the year! ✨ if you’d like to find out more information on Endocrine Oncology visit eo.bioscientifica.com
Reposted by Po Hien Ear, PhD
Our latest Special Collection celebrates the contributions and leadership of women in Neuroendocrine Tumour science, who are breaking barriers and building legacies. Submit your article proposal to contribute to this important collection. Learn more 👉 eo.bioscientifica.com/page/Women-i...
March 5, 2025 at 10:45 AM
Our latest Special Collection celebrates the contributions and leadership of women in Neuroendocrine Tumour science, who are breaking barriers and building legacies. Submit your article proposal to contribute to this important collection. Learn more 👉 eo.bioscientifica.com/page/Women-i...
Reposted by Po Hien Ear, PhD
Cancer affects everyone and knows no boundaries. It doesn't know or care about your political affiliations or your political beliefs. #CancerResearch and #Research of all kinds are the lifeblood of progress.
Halting progress without cause is unacceptable.
www.science.org/content/arti...
Halting progress without cause is unacceptable.
www.science.org/content/arti...
Trump hits NIH with ‘devastating’ freezes on meetings, travel, communications, and hiring
Researchers facing “a lot of uncertainty, fear, and panic”
www.science.org
January 23, 2025 at 5:29 PM
Cancer affects everyone and knows no boundaries. It doesn't know or care about your political affiliations or your political beliefs. #CancerResearch and #Research of all kinds are the lifeblood of progress.
Halting progress without cause is unacceptable.
www.science.org/content/arti...
Halting progress without cause is unacceptable.
www.science.org/content/arti...
Reposted by Po Hien Ear, PhD
New epidemiology data on gastroenteropancreatic
NETs (GEP-NETs) in the US. As I have said before and will continue saying, the incidence keeps rising (probably mostly from better diagnostic methods).
jamanetwork.com/journals/jam...
NETs (GEP-NETs) in the US. As I have said before and will continue saying, the incidence keeps rising (probably mostly from better diagnostic methods).
jamanetwork.com/journals/jam...
Gastroenteropancreatic Neuroendocrine Tumor Incidence by Sex and Age in the US
This observational study reports on a comprehensive nationwide evaluation of rising gastroenteropancreatic neuroendocrine tumor incidence in the US from 2001 to 2020.
jamanetwork.com
January 24, 2025 at 2:02 PM
New epidemiology data on gastroenteropancreatic
NETs (GEP-NETs) in the US. As I have said before and will continue saying, the incidence keeps rising (probably mostly from better diagnostic methods).
jamanetwork.com/journals/jam...
NETs (GEP-NETs) in the US. As I have said before and will continue saying, the incidence keeps rising (probably mostly from better diagnostic methods).
jamanetwork.com/journals/jam...
Reposted by Po Hien Ear, PhD
We know about what factors we can avoid, but what ones could we avoid if we knew about them? The role of the gut #microbiome has come under the microscope - Fusobacterium nucleatum and a few other culprits are implicated, but why are they there?
2/n #OnlyOncsInTheSymposium #GI25
2/n #OnlyOncsInTheSymposium #GI25
This morning's #GI25 session kicked off with "Personalized Risk Assessment for GI Cancers." Hereditary risk as a cause for these cancers is low (<10%); modifiable risk factors such as tobacco, alcohol, diabetes, obesity and others are known; and there are more coming to light... 1/n
January 24, 2025 at 5:50 PM
We know about what factors we can avoid, but what ones could we avoid if we knew about them? The role of the gut #microbiome has come under the microscope - Fusobacterium nucleatum and a few other culprits are implicated, but why are they there?
2/n #OnlyOncsInTheSymposium #GI25
2/n #OnlyOncsInTheSymposium #GI25
Reposted by Po Hien Ear, PhD
🔬 Join #ASOChat: Exploring breakthrough NET research!
Dr. Howe & Dr. Halfdanarson discuss "PRRT Improves Survival in Patients Who Progress After Resection of GEPNETs" - new findings in #JournalASO
📅 Jan 30, 6-7PM EST
📍 Live on X & BlueSky
#NETs #SurgOnc #MedTwitter
Dr. Howe & Dr. Halfdanarson discuss "PRRT Improves Survival in Patients Who Progress After Resection of GEPNETs" - new findings in #JournalASO
📅 Jan 30, 6-7PM EST
📍 Live on X & BlueSky
#NETs #SurgOnc #MedTwitter
January 24, 2025 at 9:15 PM
🔬 Join #ASOChat: Exploring breakthrough NET research!
Dr. Howe & Dr. Halfdanarson discuss "PRRT Improves Survival in Patients Who Progress After Resection of GEPNETs" - new findings in #JournalASO
📅 Jan 30, 6-7PM EST
📍 Live on X & BlueSky
#NETs #SurgOnc #MedTwitter
Dr. Howe & Dr. Halfdanarson discuss "PRRT Improves Survival in Patients Who Progress After Resection of GEPNETs" - new findings in #JournalASO
📅 Jan 30, 6-7PM EST
📍 Live on X & BlueSky
#NETs #SurgOnc #MedTwitter
Reposted by Po Hien Ear, PhD
AACR President-Elect Lillian Siu, MD, FAACR, explains how precision medicine could advance in 2025, including a new era for drugging the undruggable, better predicting treatment response, and more: www.aacr.org/blog/2025/01...
January 24, 2025 at 6:39 PM
AACR President-Elect Lillian Siu, MD, FAACR, explains how precision medicine could advance in 2025, including a new era for drugging the undruggable, better predicting treatment response, and more: www.aacr.org/blog/2025/01...
I’m very honored to be a part of this!
Big thanks to Dr @kelines.bsky.social who brought us together and made it happen! She’s awesome! 👏👏👏
Big thanks to Dr @kelines.bsky.social who brought us together and made it happen! She’s awesome! 👏👏👏
Po Hien Ear et al. highlight key insights from @socendocrinology.bsky.social's NET Models 2024. Experts discussed the current state of #neuroendocrine #tumor models, their limitations, and improvements for the future. Read it here 👉 https://doi.org/10.1530/EO-24-0055
January 26, 2025 at 4:11 AM
I’m very honored to be a part of this!
Big thanks to Dr @kelines.bsky.social who brought us together and made it happen! She’s awesome! 👏👏👏
Big thanks to Dr @kelines.bsky.social who brought us together and made it happen! She’s awesome! 👏👏👏
Super exciting! Highly recommended!
January 25, 2025 at 5:10 AM
Super exciting! Highly recommended!
Reposted by Po Hien Ear, PhD
Imatinib and the dawn of precision cancer therapy
Brian J. Druker describes how his research on imatinib validated protein kinases as therapeutic targets for cancer and led to a life-saving treatment for leukemia.
www.nature.com/articles/s41...
Brian J. Druker describes how his research on imatinib validated protein kinases as therapeutic targets for cancer and led to a life-saving treatment for leukemia.
www.nature.com/articles/s41...
Imatinib and the dawn of precision cancer therapy - Nature Medicine
Brian J. Druker describes how his research on imatinib validated protein kinases as therapeutic targets for cancer and led to a life-saving treatment for leukemia.
www.nature.com
January 25, 2025 at 1:41 AM
Imatinib and the dawn of precision cancer therapy
Brian J. Druker describes how his research on imatinib validated protein kinases as therapeutic targets for cancer and led to a life-saving treatment for leukemia.
www.nature.com/articles/s41...
Brian J. Druker describes how his research on imatinib validated protein kinases as therapeutic targets for cancer and led to a life-saving treatment for leukemia.
www.nature.com/articles/s41...
Happy New Year!
Bonne Année!🥳
Bonne Année!🥳
January 1, 2025 at 4:29 AM
Happy New Year!
Bonne Année!🥳
Bonne Année!🥳
My 1st time processing a Merkel Cell Carcinoma: What is that brown paste?
December 10, 2024 at 5:43 PM
My 1st time processing a Merkel Cell Carcinoma: What is that brown paste?
Reposted by Po Hien Ear, PhD
Just finished a wonderful trip to my old stomping grounds at the University of Iowa to lecture on CUPs.
Did you know, they are looking for a NET oncologist…? If you or someone you know is interested, please check them out. That’s the institution that started my NET career 😍
Did you know, they are looking for a NET oncologist…? If you or someone you know is interested, please check them out. That’s the institution that started my NET career 😍
December 9, 2024 at 10:52 PM
Just finished a wonderful trip to my old stomping grounds at the University of Iowa to lecture on CUPs.
Did you know, they are looking for a NET oncologist…? If you or someone you know is interested, please check them out. That’s the institution that started my NET career 😍
Did you know, they are looking for a NET oncologist…? If you or someone you know is interested, please check them out. That’s the institution that started my NET career 😍
Reposted by Po Hien Ear, PhD
🚨 Tenure track positions at Physiology Dept UMN.
Join a vibrant research environment:
med.umn.edu/physiology
med.umn.edu/aging
med.umn.edu/about/center...
Areas of interest: aging biology, molecular metabolism, cardiovascular, inflammation, stress etc.
Apply here: z.umn.edu/9zxj
Join a vibrant research environment:
med.umn.edu/physiology
med.umn.edu/aging
med.umn.edu/about/center...
Areas of interest: aging biology, molecular metabolism, cardiovascular, inflammation, stress etc.
Apply here: z.umn.edu/9zxj
November 23, 2024 at 6:20 AM
🚨 Tenure track positions at Physiology Dept UMN.
Join a vibrant research environment:
med.umn.edu/physiology
med.umn.edu/aging
med.umn.edu/about/center...
Areas of interest: aging biology, molecular metabolism, cardiovascular, inflammation, stress etc.
Apply here: z.umn.edu/9zxj
Join a vibrant research environment:
med.umn.edu/physiology
med.umn.edu/aging
med.umn.edu/about/center...
Areas of interest: aging biology, molecular metabolism, cardiovascular, inflammation, stress etc.
Apply here: z.umn.edu/9zxj